80 FR 53548 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 172 (September 4, 2015)

Page Range		53548-53549
FR Document		2015-21940

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 80 Issue 172 (Friday, September 4, 2015)

[Federal Register Volume 80, Number 172 (Friday, September 4, 2015)]
[Notices]
[Pages 53548-53549]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-21940]



[[Page 53548]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to 
receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

Live Attenuated Vaccine To Prevent Disease Caused by West Nile Virus

    Description of Technology: West Nile virus (WNV) has recently 
emerged in the U.S. and is considered a significant emerging disease 
that has embedded itself over a considerable region of the U.S. WNV 
infections have been recorded in humans as well as in different 
animals. From 1999-2014, WNV killed 1,765 people in the U.S. and caused 
severe disease in more than 41,762 others. This project is part of 
NIAID's comprehensive emerging infectious disease program.
    The methods and compositions of this invention provide a means for 
prevention of WNV infection by immunization with attenuated, 
immunogenic viral vaccines against WNV. The invention involves a 
chimeric virus form comprising parts of WNV and Dengue virus. 
Construction of the hybrids and their properties are described in 
detail in multiple publications. The WNV chimeric vaccine does not 
target the central nervous system, which would be the case in an 
infection with wild type WNV. Importantly, two successful Phase I 
clinical trials were recently carried out with the vaccine. The live 
attenuated WNV vaccine is safe, well-tolerated, and immunogenic in 
healthy adult volunteers. Furthermore, the vaccine virus may also be 
considered for use as a safe reagent handled at bio-safety level 2 
facilities for WNV diagnosis and surveillance.

Potential Commercial Applications

 Human West Nile vaccine
 Veterinary West Nile vaccine
 West Nile Virus diagnostics
 West Nile Virus therapeutics

Competitive Advantages

 Low cost of manufacture
 Proven chimeric vaccine technology
 Phase I clinical data available

Development Stage

 In vivo data available (animal)
 In vivo data available (human)

    Inventors: Alexander G. Pletnev, Robert M. Chanock, Joseph R. 
Putnak, Brian R. Murphy, Joseph E. Blaney, Stephen S. Whitehead (all of 
NIAID)

Publications

1. Pletnev AG, et al. West Nile virus/dengue type 4 virus chimeras 
that are reduced in neurovirulence and peripheral virulence without 
loss of immunogenicity or protective efficacy. Proc Natl Acad Sci 
USA. 2002 Mar 5;99(5):3036-41. [PMID 11880643]
2. Pletnev AG, et al. Molecularly engineered live-attenuated 
chimeric West Nile/dengue virus vaccines protect rhesus monkeys from 
West Nile virus. Virology. 2003 Sep 15;314(1):190-5. [PMID 14517072]
3. Hanley KA, et al. Infectivity of West Nile/dengue chimeric 
viruses for West Nile and dengue mosquito vectors. Vector Borne 
Zoonotic Dis. 2005 Spring;5(1):1-10. [PMID 15815144]
4. Pletnev AG, et al. Chimeric West Nile/dengue virus vaccine 
candidate: preclinical evaluation in mice, geese and monkeys for 
safety and immunogenicity. Vaccine. 2006 Sep 29;24(40-41):6392-404. 
[PMID 16831498]
5. Durbin AP, et al. The live attenuated chimeric vaccine rWN/
DEN4delta30 is well-tolerated and immunogenic in healthy flavivirus-
na[iuml]ve adult volunteers. Vaccine. 2013 Nov 19;31(48):5772-7. 
[PMID 23968769]
6. Maximova OA, et al. Assurance of neuroattenuation of a live 
vaccine against West Nile virus: a comprehensive study of 
neuropathogenesis after infection with chimeric WN/DEN4delta30 
vaccine in comparison to two parental viruses and a surrogate 
flavivirus reference vaccine. Vaccine. 2014 May 30;32(26):3187-97. 
[PMID 24736001]

    Intellectual Property: HHS Reference No. E-357-2001/1--

 US Patent No. 8,778,671 issued 15 Jul 2014
 US Patent Application No. 14/305,572 filed 16 Jun 2014
 Various international patents/applications issued/pending

    Licensing Contact: Peter Soukas; 301-435-4646; [email protected].

Three-Dimensional Curved Catheter for Right Atrial Appendage Traversal

    Description of Technology: Available for licensing and commercial 
development is a three-dimensionally configured curved catheter for 
safe traversal of the right atrial appendage (RAA). The device is 
configured to optimize one-way access of the pericardial space through 
the right atrium and into the RAA reducing the risk of coronary 
lacerations. Specifically the curved catheter is best described in 
three segments: a proximal segment, a transitional segment and a distal 
segment; the transition segment having a clockwise spiral shaped 
curvature. When inserted into a patient, the proximal segment is 
positioned within the inferior vena cava, the transition segment 
extends across the caval-atrial junction and curves rightward, forward, 
and upward such that the catheter abuts a right lateral wall of the 
right atrium, and the distal segment curves leftward, forward, and 
upward from the transition segment through the right atrium such that 
the catheter abuts an anterior wall of the right atrium adjacent to the 
RAA. The catheter is configured to guide a coaxial puncturing device to 
through the superior left sulcal wall of the RAA.

Potential Commercial Applications

 Left atrial appendage ligation
 Circumferential tricuspid annuloplasty
 Epicardial ablation
Competitive Advantages: Reduced risk of coronary or myocardial 
laceration

Development Stage

 Early-stage
 Prototype

    Inventors: Robert Lederman (NHLBI), Toby Rogers (NHLBI), Nasser 
Rafiee (Mehr Medical), Adam Greenbaum (Henry Ford Hospital), William 
O'Neill (Henry Ford Hospital).
    Intellectual Property: HHS Reference No. E-078-2015--US Provisional 
Patent Application 62/162,453 filed May 15, 2015.
    Related Technologies: HHS Reference No. E-027-2013; HHS Reference 
No. E-115-2013; HHS Reference No. E-018-2014; and HHS Reference Nos. E-
068-2014/E-124-2014.

[[Page 53549]]

    Licensing Contact: Michael Shmilovich, Esq.; 301-435-5019; 
[email protected]
    Collaborative Research Opportunity: The National Heart, Lung and 
Blood Institute is seeking statements of capability or interest from 
parties interested in collaborative research to further develop, 
evaluate or commercialize devices for pericardial interventional 
procedures. For collaboration opportunities, please contact Peg Koelble 
at 301-594-4095 or [email protected].

Pseudomonas Exotoxin A With Modified Furin Cleavage Site

    Description of Technology: Immunotoxins kill cancer cells while 
allowing healthy, essential cells to survive. As a result, patients 
receiving immunotoxins are less likely to experience the deleterious 
side-effects associated with non-specific therapies such as 
chemotherapy. In order to make an effective immunotoxin, three 
components are generally required: A targeting domain, a furin cleavage 
site (FCS), and a toxic payload molecule (such as Pseudomonas exotoxin 
A (PE)). The purpose of the FCS is to allow the toxin domain to be 
processed by the target cell so that it can exert its toxic effect. 
This technology concerns the engineering of FCS in order to improve the 
efficacy of specific immunotoxins having distinct targeting domains. 
Several novel FCS have been generated which can be substituted for the 
native FCS in PE. By using specific FCS with different targeting 
moieties, it is possible to engineer an immunotoxin that is better 
suited to treating specific types of cancer.

Potential Commercial Applications

 Essential for the payload component of immunotoxins
 Treatment of any disease associated with increased or 
preferential expression of a specific cell surface receptor
 Specific diseases include hematological cancers, lung cancer 
(including mesothelioma), ovarian cancer, breast cancer, and head and 
neck cancers

Competitive Advantages

 Designing specific furin cleavage sites for particular 
immunotoxins can improve cleavage and enhance toxin efficacy, resulting 
in improved therapeutic effectiveness
 Targeted therapy decreases non-specific killing of healthy, 
essential cells, resulting in fewer non-specific side-effects and 
healthier patients

    Development Stage: In vitro data available.
    Inventors: Ira Pastan et al. (NCI).

Publications

1. Weldon JE, et al. Designing the furin-cleavable linker in 
recombinant immunotoxins based on Pseudomonas exotoxin A. Bioconjug 
Chem. 2015 Jun 17;26(6):1120-8. [PMID 25997032]
2. Weldon JE, et al. A protease-resistant immunotoxin against CD22 
with greatly increased activity against CLL and diminished animal 
toxicity'' Blood. 2009 Apr 16;113(16):3792-800. [PMID 18988862]

    Intellectual Property: HHS Reference No. E-197-2015/0-US-01--US 
Provisional Application No. 62/163,667 filed May 19, 2015.

Related Technologies

 HHS Reference E-262-2005/0
 HHS Reference E-292-2007/0
 HHS Reference E-269-2009/0
 HHS Reference E-174-2011/0
 HHS Reference E-263-2011/0
    Licensing Contact: David A. Lambertson, Ph.D.; 301-435-4632; 
[email protected].
    Collaborative Research Opportunity: The National Cancer Institute 
is seeking statements of capability or interest from parties interested 
in collaborative research to further develop, evaluate or commercialize 
Pseudomonas Exotoxin A with Modified Furin Cleavage Site. For 
collaboration opportunities, please contact John D. Hewes, Ph.D. at 
[email protected].

    Dated: August 31, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-21940 Filed 9-3-15; 8:45 am]
BILLING CODE 4140-01-P

53548 Federal Register / Vol. 80, No. 172 / Friday, September 4, 2015 / Notices

DEPARTMENT OF HEALTH AND WNV. Importantly, two successful Intellectual Property: HHS Reference
HUMAN SERVICES Phase I clinical trials were recently No. E–357–2001/1—
carried out with the vaccine. The live • US Patent No. 8,778,671 issued 15 Jul
National Institutes of Health attenuated WNV vaccine is safe, well- 2014
tolerated, and immunogenic in healthy • US Patent Application No. 14/305,572
Government-Owned Inventions; adult volunteers. Furthermore, the filed 16 Jun 2014
Availability for Licensing vaccine virus may also be considered for • Various international patents/
AGENCY: National Institutes of Health, use as a safe reagent handled at bio- applications issued/pending
HHS. safety level 2 facilities for WNV Licensing Contact: Peter Soukas; 301–
ACTION: Notice. diagnosis and surveillance. 435–4646; ps193c@nih.gov.
Potential Commercial Applications Three-Dimensional Curved Catheter for
SUMMARY: The inventions listed below
• Human West Nile vaccine Right Atrial Appendage Traversal
are owned by an agency of the U.S.
Government and are available for • Veterinary West Nile vaccine Description of Technology: Available
licensing in the U.S. in accordance with • West Nile Virus diagnostics for licensing and commercial
35 U.S.C. 209 and 37 CFR part 404 to • West Nile Virus therapeutics development is a three-dimensionally
achieve expeditious commercialization configured curved catheter for safe
of results of federally-funded research Competitive Advantages traversal of the right atrial appendage
and development. Foreign patent • Low cost of manufacture (RAA). The device is configured to
applications are filed on selected • Proven chimeric vaccine technology optimize one-way access of the
inventions to extend market coverage pericardial space through the right
• Phase I clinical data available
for companies and may also be available atrium and into the RAA reducing the
for licensing. Development Stage risk of coronary lacerations. Specifically
the curved catheter is best described in
FOR FURTHER INFORMATION CONTACT: • In vivo data available (animal)
Licensing information and copies of the three segments: a proximal segment, a
• In vivo data available (human) transitional segment and a distal
U.S. patent applications listed below
may be obtained by writing to the Inventors: Alexander G. Pletnev, segment; the transition segment having
indicated licensing contact at the Office Robert M. Chanock, Joseph R. Putnak, a clockwise spiral shaped curvature.
of Technology Transfer, National Brian R. Murphy, Joseph E. Blaney, When inserted into a patient, the
Institutes of Health, 6011 Executive Stephen S. Whitehead (all of NIAID) proximal segment is positioned within
Boulevard, Suite 325, Rockville, Publications the inferior vena cava, the transition
Maryland 20852–3804; telephone: 301– segment extends across the caval-atrial
496–7057; fax: 301–402–0220. A signed 1. Pletnev AG, et al. West Nile virus/dengue junction and curves rightward, forward,
Confidential Disclosure Agreement will type 4 virus chimeras that are reduced in and upward such that the catheter abuts
be required to receive copies of the neurovirulence and peripheral virulence a right lateral wall of the right atrium,
without loss of immunogenicity or and the distal segment curves leftward,
patent applications.
protective efficacy. Proc Natl Acad Sci forward, and upward from the transition
SUPPLEMENTARY INFORMATION: USA. 2002 Mar 5;99(5):3036–41. [PMID segment through the right atrium such
Technology descriptions follow. 11880643] that the catheter abuts an anterior wall
2. Pletnev AG, et al. Molecularly engineered
Live Attenuated Vaccine To Prevent live-attenuated chimeric West Nile/
of the right atrium adjacent to the RAA.
Disease Caused by West Nile Virus dengue virus vaccines protect rhesus The catheter is configured to guide a
Description of Technology: West Nile monkeys from West Nile virus. Virology. coaxial puncturing device to through
virus (WNV) has recently emerged in 2003 Sep 15;314(1):190–5. [PMID the superior left sulcal wall of the RAA.
the U.S. and is considered a significant 14517072]
3. Hanley KA, et al. Infectivity of West Nile/
Potential Commercial Applications
emerging disease that has embedded
dengue chimeric viruses for West Nile • Left atrial appendage ligation
itself over a considerable region of the and dengue mosquito vectors. Vector • Circumferential tricuspid
U.S. WNV infections have been Borne Zoonotic Dis. 2005 Spring;5(1):1– annuloplasty
recorded in humans as well as in 10. [PMID 15815144] • Epicardial ablation
different animals. From 1999–2014, 4. Pletnev AG, et al. Chimeric West Nile/ Competitive Advantages: Reduced risk
WNV killed 1,765 people in the U.S. dengue virus vaccine candidate: of coronary or myocardial laceration
and caused severe disease in more than preclinical evaluation in mice, geese and
41,762 others. This project is part of monkeys for safety and immunogenicity. Development Stage
NIAID’s comprehensive emerging Vaccine. 2006 Sep 29;24(40–41):6392– • Early-stage
404. [PMID 16831498]
infectious disease program. • Prototype
5. Durbin AP, et al. The live attenuated
The methods and compositions of this chimeric vaccine rWN/DEN4delta30 is Inventors: Robert Lederman (NHLBI),
invention provide a means for well-tolerated and immunogenic in Toby Rogers (NHLBI), Nasser Rafiee
prevention of WNV infection by healthy flavivirus-naı̈ve adult volunteers. (Mehr Medical), Adam Greenbaum
immunization with attenuated, Vaccine. 2013 Nov 19;31(48):5772–7. (Henry Ford Hospital), William O’Neill
immunogenic viral vaccines against [PMID 23968769] (Henry Ford Hospital).
WNV. The invention involves a 6. Maximova OA, et al. Assurance of Intellectual Property: HHS Reference
neuroattenuation of a live vaccine
mstockstill on DSK4VPTVN1PROD with NOTICES

chimeric virus form comprising parts of No. E–078–2015—US Provisional Patent
WNV and Dengue virus. Construction of against West Nile virus: a comprehensive Application 62/162,453 filed May 15,
the hybrids and their properties are study of neuropathogenesis after
infection with chimeric WN/
2015.
described in detail in multiple DEN4delta30 vaccine in comparison to
Related Technologies: HHS Reference
publications. The WNV chimeric two parental viruses and a surrogate No. E–027–2013; HHS Reference No. E–
vaccine does not target the central flavivirus reference vaccine. Vaccine. 115–2013; HHS Reference No. E–018–
nervous system, which would be the 2014 May 30;32(26):3187–97. [PMID 2014; and HHS Reference Nos. E–068–
case in an infection with wild type 24736001] 2014/E–124–2014.

VerDate Sep<11>2014 16:57 Sep 03, 2015 Jkt 235001 PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 E:\FR\FM\04SEN1.SGM 04SEN1

Federal Register / Vol. 80, No. 172 / Friday, September 4, 2015 / Notices 53549

Licensing Contact: Michael Potential Commercial Applications • HHS Reference E–292–2007/0
Shmilovich, Esq.; 301–435–5019; • Essential for the payload component • HHS Reference E–269–2009/0
shmilovm@mail.nih.gov of immunotoxins • HHS Reference E–174–2011/0
Collaborative Research Opportunity: • Treatment of any disease associated • HHS Reference E–263–2011/0
The National Heart, Lung and Blood with increased or preferential Licensing Contact: David A.
Institute is seeking statements of expression of a specific cell surface Lambertson, Ph.D.; 301–435–4632;
capability or interest from parties receptor lambertsond@mail.nih.gov.
interested in collaborative research to • Specific diseases include Collaborative Research Opportunity:
hematological cancers, lung cancer The National Cancer Institute is seeking
further develop, evaluate or
(including mesothelioma), ovarian statements of capability or interest from
commercialize devices for pericardial
cancer, breast cancer, and head and parties interested in collaborative
interventional procedures. For
neck cancers research to further develop, evaluate or
collaboration opportunities, please commercialize Pseudomonas Exotoxin
contact Peg Koelble at 301–594–4095 or Competitive Advantages A with Modified Furin Cleavage Site.
koelblep@nhlbi.nih.gov. • Designing specific furin cleavage sites For collaboration opportunities, please
Pseudomonas Exotoxin A With for particular immunotoxins can contact John D. Hewes, Ph.D. at
Modified Furin Cleavage Site improve cleavage and enhance toxin hewesj@mail.nih.gov.
efficacy, resulting in improved Dated: August 31, 2015.
Description of Technology: therapeutic effectiveness Richard U. Rodriguez,
Immunotoxins kill cancer cells while • Targeted therapy decreases non-
Acting Director, Office of Technology
allowing healthy, essential cells to specific killing of healthy, essential Transfer, National Institutes of Health.
survive. As a result, patients receiving cells, resulting in fewer non-specific
[FR Doc. 2015–21940 Filed 9–3–15; 8:45 am]
immunotoxins are less likely to side-effects and healthier patients
BILLING CODE 4140–01–P
experience the deleterious side-effects Development Stage: In vitro data
associated with non-specific therapies available.
such as chemotherapy. In order to make Inventors: Ira Pastan et al. (NCI). DEPARTMENT OF HEALTH AND
an effective immunotoxin, three Publications HUMAN SERVICES
components are generally required: A
targeting domain, a furin cleavage site 1. Weldon JE, et al. Designing the furin- National Institutes of Health
(FCS), and a toxic payload molecule cleavable linker in recombinant
(such as Pseudomonas exotoxin A (PE)). immunotoxins based on Pseudomonas Prospective Grant of an Exclusive
The purpose of the FCS is to allow the exotoxin A. Bioconjug Chem. 2015 Jun Patent Commercialization License:
toxin domain to be processed by the 17;26(6):1120–8. [PMID 25997032] Cerclage Annuloplasty Devices for
2. Weldon JE, et al. A protease-resistant Treating Mitral Valve Regurgitation
target cell so that it can exert its toxic immunotoxin against CD22 with greatly
effect. This technology concerns the increased activity against CLL and AGENCY: National Institutes of Health,
engineering of FCS in order to improve diminished animal toxicity’’ Blood. 2009 HHS.
the efficacy of specific immunotoxins Apr 16;113(16):3792–800. [PMID ACTION: Notice.
having distinct targeting domains. 18988862]
Several novel FCS have been generated Intellectual Property: HHS Reference SUMMARY: This is notice, in accordance
which can be substituted for the native No. E–197–2015/0–US–01—US with 35 U.S.C. 209 and 37 CFR 404, that
FCS in PE. By using specific FCS with Provisional Application No. 62/163,667 the National Institutes of Health (NIH),
different targeting moieties, it is filed May 19, 2015. Department of Health and Human
possible to engineer an immunotoxin Services, is contemplating the grant of a
that is better suited to treating specific Related Technologies worldwide exclusive license to practice
types of cancer. • HHS Reference E–262–2005/0 the inventions embodied in:

NIH Ref No. Patent application No. Filing date Title

E–048–2009/0–US–01 ................ 61/157,267 ................................ March 4, 2009 ........................... Cerclage Locking Device And Delivery
System.
E–048–2009/0–PCT–02 .............. PCT/US2010/026245 ................ March 4, 2010 ........................... Cerclage Locking Device And Delivery
System.
E–048–2009/0–US–03 ................ 13/254,160 ................................ March 4, 2010 ........................... Cerclage Locking Device And Delivery
System.
E–108–2010/0–US–01 ................ 61/383,061 ................................ September 15, 2010 ................. Methods and Devices For Transcatheter
Cerclage Annuloplasty.
E–108–2010/0–PCT–02 .............. PCT/US2011/51748 .................. September 15, 2011 ................. Methods and Devices For Transcatheter
Cerclage Annuloplasty.
E–108–2010/0–EP–03 ................ 11760945.3 ............................... September 15, 2011 ................. Methods and Devices For Transcatheter
Cerclage Annuloplasty.
E–108–2010/0–US–04 ................ 13/824,198 ................................ March 15, 2013 ......................... Methods and Devices For Transcatheter
Cerclage Annuloplasty.
mstockstill on DSK4VPTVN1PROD with NOTICES

To Transmural Systems, LLC, a limited The contemplated exclusive license DATES: Only written comments and/or
liability company incorporated under may be limited to cerclage annuloplasty applications for a license that are
the laws of the State of Massachusetts devices for treating mitral valve received by the NIH Office of
and having its principle place of regurgitation. Technology Transfer on or before
business in Andover, Massachusetts. October 5, 2015 will be considered.

VerDate Sep<11>2014 16:57 Sep 03, 2015 Jkt 235001 PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 E:\FR\FM\04SEN1.SGM 04SEN1

Document Created: 2015-12-15 09:58:03
Document Modified: 2015-12-15 09:58:03

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Dates		preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine. 2006 Sep 29;24(40-41):6392-404. [PMID 16831498] 5. Durbin AP, et al. The live attenuated chimeric vaccine rWN/ DEN4delta30 is well-tolerated and immunogenic in healthy flavivirus- na[iuml]ve adult volunteers. Vaccine. 2013 Nov 19;31(48):5772-7. [PMID 23968769] 6. Maximova OA, et al. Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4delta30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine. Vaccine. 2014 May 30;32(26):3187-97. [PMID 24736001]
Contact		Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402- 0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
FR Citation		80 FR 53548

80 FR 53548 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 80, Issue 172 (September 4, 2015)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health